Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
4 hedge funds and large institutions have $99K invested in Hepion Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
33% less funds holding
Funds holding: 6 → 4 (-2)
54% less capital invested
Capital invested by funds: $215K → $99K (-$116K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$38.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$27K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$19.4K |
| 4 |
VF
Virtu Financial
New York
|
-$19.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
HighTower Advisors
Chicago,
Illinois
| $23K | -$19.4K | -1 | -50% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $23K | – | – | – |
|
|
3
Barclays
London,
United Kingdom
| $19K | -$38.7K | -2 | -67% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $14K | – | – | – |
|
|
CS
5
Credit Suisse
Zurich,
Switzerland
| $5K | – | – | – |
|
6
Northern Trust
Chicago,
Illinois
| $4K | – | – | – |
|
|
PFS
7
Prospera Financial Services
Dallas,
Texas
| $4K | – | – | – |
|
|
VF
8
Virtu Financial
New York
| $3K | -$19.4K | -1 | Closed |
|
9
BlackRock
New York
| $1K | – | – | – |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
11
Morgan Stanley
New York
| $1K | – | – | – |
|
12
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$27K | -1 | Closed |
|
|
PP
14
Paloma Partners
Greenwich,
Connecticut
| – | -$6K | – | – |
|
|
TSS
15
Two Sigma Securities
New York
| – | -$7K | – | – |
|
HEPA Hedge Fund Activity: Q1 2019 in Review
4 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2019, worth a combined $99K — down 54% from $215K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of HEPA and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Barclays, cutting an estimated $38.7K.
- 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2019, down from 6 in Q4 2018.
- Funds reported $99K of Hepion Pharmaceuticals stock for Q1 2019, down 54% quarter-over-quarter.
- 0 funds opened new Hepion Pharmaceuticals positions in Q1 2019 and 2 closed out, a net change of -2 holders.
- The largest Hepion Pharmaceuticals seller in Q1 2019 was Barclays, an estimated $38.7K sold.
Based on aggregated 13F filings for Q1 2019.